JHL Biotech and Switzerland-based Selexis SA have signed a non-exclusive strategic agreement to provide services for the development and cGMP manufacture of biologic drugs. The alliance will have a special focus on delivering high-quality biologics to the Chinese market.   The alliance will allow customers to go from drug candidate DNA to active pharmaceutical ingredient (API), and into clinical development and commercialization. Selexis will provide the fully documented SURE CHO-M mammalian clo...